Zavicefta

For single use.​‍​​​​​‍​‍‍‍‍​‍‍ Discard any unused contents. Instructions for reconstitution: See table for addition volumes and solution concentrations, which may be useful when fractional doses are required. PREPARATION OF SOLUTION INTRAMUSCULAR INJECTION Strength Diluent Amount of diluent to be added (ml) Approximate concentration (mg/ml) Approximate available volume (ml) Approximate displacement volume (ml) 1 g 0.5% lidocaine 3 ml 278 3.6 ml 0.6 ml 1 g 1% lidocaine 3 ml 270 3.7 ml 0.7 ml INTRAVENOUS BOLUS Strength Diluent Amount of diluent to be added (ml) Approximate concentration (mg/ml) Approximate available volume (ml) Approximate displacement volume (ml) 1 g Water for Injection 10 ml 92 10.9 ml 0.9 ml INTRAVENOUS INFUSION Strength Diluent Amount of diluent to be added (ml) # Approximate concentration (mg/ml) 1 g See list of compatible diluents below 50 ml 20 # Note: addition should be in two stages. See preparation for intravenous infusion instructions below. Compatible diluents for intravenous infusion Ceftazidime at concentrations between 1 mg/ml and 40 mg/ml is compatible with the following diluent solutions for intravenous infusion preparation: Sodium Chloride 0.9% Ringer Solution Ringer Lactate Solution Glucose 5% Glucose 10% Glucose 5% and Sodium Chloride 0.9% Glucose 5% and Sodium Chloride 0.45% Glucose 5% and Sodium Chloride 0.2% Dextran 40%/10% and Sodium Chloride 0.9% Dextran 70%/6% and Sodium Chloride 0.9% Solutions range from light yellow to amber depending on concentration, diluent and storage conditions used. All sizes of vials as supplied are under reduced pressure. As the product dissolves, carbon dioxide is released and a positive pressure develops. For ease of use, it is recommended that the following techniques of reconstitution are adopted. Preparation of solution for bolus injection: 1. Insert the syringe needle through the vial closure and inject 10 ml of Water for Injection. The vacuum may assist entry of the diluent. Remove the syringe needle. 2. Shake to dissolve: carbon dioxide is released and a clear solution will be obtained in about 1 to 2 minutes. 3. Invert the vial. With the syringe plunger fully depressed, insert the needle through the vial closure and withdraw the total volume of solution into the syringe (the pressure in the vial may aid withdrawal). Ensure that the needle remains within the solution and does not enter the head space. The withdrawn solution may contain small bubbles of carbon dioxide; they may be disregarded. These solutions may be given directly into the vein or introduced into the tubing of a giving set if the patient is receiving parenteral fluids. Preparation of solution for intravenous infusion: Prepare using a total of 50 ml of compatible diluent, added in TWO stages as follows: 1. Insert the syringe needle through the vial closure and inject 10ml of Water for Injection or one of the listed compatible diluent solutions for intravenous infusion preparation to reconstitute. The vacuum may assist entry of the diluent. Remove the syringe needle. 2. Shake to dissolve: carbon dioxide is released and a clear solution obtained in about 1 to 2 minutes. 3. Do not insert a gas relief needle until the product has dissolved. Insert a gas relief needle through the vial closure to relieve the internal pressure. 4. Transfer the reconstituted solution to the final delivery vehicle (e.g. mini-bag or burette-type set) and add 40ml of compatible diluent* to make up a total volume of approximately 50ml and administer by slow intravenous infusion over 20 to 30 minutes. * For the second stage of preparation use Sodium Chloride 0.9%, Glucose 5% or one of the listed compatible diluent solutions for intravenous infusion preparation, as Water for Injection produces hypotonic solutions when used at higher concentrations. Ceftazidime at concentrations between 1 mg/ml and 40 mg/ml is compatible with the diluent solutions for intravenous infusion preparation listed above. NOTE: To preserve product sterility, it is important that a gas relief needle is not inserted through the vial closure before the product has dissolved.